Suppr超能文献

1型糖尿病患者中非酒精性脂肪性肝病的患病率及其相关因素:巴西一家三级医疗中心的横断面研究

Prevalence of non-alcoholic fatty liver disease and its associated factors in individuals with type 1 diabetes: a cross-sectional study in a tertiary care center in Brazil.

作者信息

Barros Bianca Senger Vasconcelos, Monteiro Fernanda Cruz, Terra Carlos, Gomes Marilia Brito

机构信息

Department of Internal Medicine, Diabetes Unit, Pedro Ernesto Hospital, State University of Rio de Janeiro (UERJ), 20.551-030, Boulevard 28 de Setembro, 77 - 3º andar - Vila Isabel, Rio de Janeiro, RJ, CEP 20551-030, Brazil.

Department of Radiology, Pedro Ernesto Hospital, State University of Rio de Janeiro (UERJ), 20.551-030, Rio de Janeiro, RJ, Brazil.

出版信息

Diabetol Metab Syndr. 2021 Mar 19;13(1):33. doi: 10.1186/s13098-021-00649-0.

Abstract

BACKGROUND

Data on non-alcoholic fatty liver disease (NAFLD) in individuals with type 1 diabetes (T1D) is controversial and so far, there are no published data on the Brazilian population. We investigated the prevalence of steatosis and hepatic fibrosis in a population with T1D from a tertiary care center in Brazil and its associated factors.

METHODS

Ninety-five participants with T1D, aged 39 ± 13 years, with disease duration of 21 ± 9 years, being 55 (57.9%) females, from a university hospital in Rio de Janeiro, were screened for NAFLD with hepatic ultrasound (US) and transient elastography (TE).

RESULTS

Prevalence of steatosis was, respectively, 12.6% and 16.8% when US and TE were used for diagnosis of NAFLD. Fibrosis was present in 8.4% of participants. A total of 31.6% of participants had at least one of the hepatic exams altered, which was associated with higher body mass index, waist circumference, hip circumference and waist-to-hip ratio,, presence of metabolic syndrome and higher triglycerides levels, even within the normal range. After multivariate analysis, presence of steatosis was only associated with metabolic syndrome and its component, triglycerides.

CONCLUSION

In our study, prevalence of NAFLD in ultrasound approximates the one found with TE. Fibrosis was not frequent. Screening should be reserved for participants with T1D and metabolic syndrome, as this was the main factor associated with NAFLD. Triglycerides levels were the only component of metabolic syndrome associated with steatosis. Further studies are necessary to determine the best screening strategy for NAFLD in individuals with T1D. Also, predisposing factors for development in fibrosis in T1D should be further explored in prospective studies.

摘要

背景

1型糖尿病(T1D)患者中非酒精性脂肪性肝病(NAFLD)的数据存在争议,迄今为止,巴西人群中尚无相关发表数据。我们调查了巴西一家三级医疗中心的T1D患者人群中脂肪变性和肝纤维化的患病率及其相关因素。

方法

对来自里约热内卢一家大学医院的95名T1D患者进行筛查,这些患者年龄为39±13岁,病程为21±9年,其中55名(57.9%)为女性,采用肝脏超声(US)和瞬时弹性成像(TE)对其进行NAFLD筛查。

结果

当使用US和TE诊断NAFLD时,脂肪变性的患病率分别为12.6%和16.8%。8.4%的参与者存在纤维化。共有31.6%的参与者至少有一项肝脏检查结果异常,这与较高的体重指数、腰围、臀围和腰臀比、代谢综合征的存在以及较高的甘油三酯水平相关,即使甘油三酯水平在正常范围内。多因素分析后,脂肪变性仅与代谢综合征及其组分甘油三酯相关。

结论

在我们的研究中,超声检查中NAFLD的患病率与TE检查结果相近。纤维化并不常见。应仅对患有T1D和代谢综合征的参与者进行筛查,因为这是与NAFLD相关的主要因素。甘油三酯水平是与脂肪变性相关的代谢综合征的唯一组分。有必要进行进一步研究以确定T1D患者中NAFLD的最佳筛查策略。此外,应在前瞻性研究中进一步探索T1D患者发生肝纤维化的易感因素。

相似文献

2
Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes.
Eur J Intern Med. 2022 Jun;100:77-82. doi: 10.1016/j.ejim.2022.03.025. Epub 2022 Apr 3.
3
Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes.
JHEP Rep. 2023 Apr 7;5(7):100753. doi: 10.1016/j.jhepr.2023.100753. eCollection 2023 Jul.
4
The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population.
J Clin Gastroenterol. 2017 Feb;51(2):160-166. doi: 10.1097/MCG.0000000000000666.
6
Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women.
Climacteric. 2014 Dec;17(6):692-9. doi: 10.3109/13697137.2014.926323. Epub 2014 Aug 7.
10
Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women.
Climacteric. 2014 Aug;17(4):465-71. doi: 10.3109/13697137.2014.881353. Epub 2014 Feb 11.

引用本文的文献

2
Type 1 diabetes in Brazil: a narrative overview of the Brazilian Type 1 Diabetes Study Group.
Diabetol Metab Syndr. 2025 May 24;17(1):166. doi: 10.1186/s13098-025-01708-6.
3
Risk Factors Related to the Development of Nonalcoholic Fatty Liver: A Systematic Review.
Can J Gastroenterol Hepatol. 2025 Apr 15;2025:9964486. doi: 10.1155/cjgh/9964486. eCollection 2025.
4
Type 1 diabetes and combined acute and chronic complications are associated with risk of progression of liver fibrosis: a Mendelian randomization study.
Front Endocrinol (Lausanne). 2024 Aug 5;15:1302611. doi: 10.3389/fendo.2024.1302611. eCollection 2024.
5
Hospital admissions for chronic liver diseases: a temporal study in the South Region of Brazil.
Rev Assoc Med Bras (1992). 2024 May 20;70(5):e20231430. doi: 10.1590/1806-9282.20231430. eCollection 2024.
6
Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes.
JHEP Rep. 2023 Apr 7;5(7):100753. doi: 10.1016/j.jhepr.2023.100753. eCollection 2023 Jul.
10
Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy.
Front Pharmacol. 2021 Oct 25;12:768576. doi: 10.3389/fphar.2021.768576. eCollection 2021.

本文引用的文献

2
The epidemiology of obesity.
Metabolism. 2019 Mar;92:6-10. doi: 10.1016/j.metabol.2018.09.005. Epub 2018 Sep 22.
3
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms.
Endocr Rev. 2018 Oct 1;39(5):629-663. doi: 10.1210/er.2017-00191.
4
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.
Nat Rev Endocrinol. 2018 Feb;14(2):99-114. doi: 10.1038/nrendo.2017.173. Epub 2017 Dec 29.
5
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
7
Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes.
J Diabetes Complications. 2017 Jun;31(6):1021-1026. doi: 10.1016/j.jdiacomp.2017.01.024. Epub 2017 Feb 12.
8
9
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28.
10
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
Am J Gastroenterol. 2017 Jan;112(1):18-35. doi: 10.1038/ajg.2016.517. Epub 2016 Dec 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验